Screen: 26
Patient characteristics | N (%) | |
Sex | Men / Women | 28 (66.7%) / 14 (33.3%) |
Age | Median (range) (years) | 68 (33-84) |
Pathology | Adenocarcinoma | 34 (90.0%) |
Squamous cell carcinoma | 4 (9.5%) | |
Pleomorphic carcinoma | 1 (2.4%) | |
Large cell carcinoma | 1 (2.4%) | |
NSCLC, NOS | 2 (4.8%) | |
EGFR mutation | Positive / negative | 13 (31.0%) / 29 (69.0%) |
Primary site | Controlled / uncontrolled | 16 (38.1%) / 26 (61.9%) |
Extracranial metastases | Yes / No | 39 (92.9%) / 3 (7.1%) |
No. of BMs | 1 / 2 / >3 | 2 (4.8%) / 2 (4.8%) / 38 (90.5%) |
Maximum BM size | median (range) (mm) | 15 (4-55) |
TKI usage after RT | Yes / No | 9 (21.4%) / 33 (78.6%) |
Hidekazu Tanaka, MD, PhD
Yamaguchi University Graduate School of Medicine
Ube, Yamaguchi